Chimeric Antigen Receptor T-cell Therapy, CAR-T, is a type of cancer immunotherapy that has gained world-wide interest in recent years, especially after FDA approval of CAR-T treatments for B-cell acute lymphoblastic leukemia and large B-cell non-Hodgkin’s lymphoma. To ensure the safety of the CAR-T treatment, regulatory agencies require thorough characterization of the manufactured CAR T-Cells. In addition, during the clinical trial or patient treatment phase, the level of modified T-cells in patients’ blood must be monitored frequently in a timely manner.
Avance Biosciences is experienced in the monitoring, evaluation and quantitation of RNA in animal tissues or in human blood to support our clients’ pharmacokinetic studies. Our study directors and lab analysts are proficient in qPCR assay design and validation, for both relative and absolute quantification of RNAs.
Our Customers Say…
From the preliminary conclusion of this work, we are already pleased to thank you for your customer-oriented approach and proactive communication in the course of this study. We are happy to see the profound difference in business mindset between your organization and our previous vendor…
Project Manager, Belgium
Thank you so much for successfully completing this important project for us on time. We are very satisfied with the final report and thank you for taking the extra effort to customize the report format. We will definitely use your lab for future projects.
Program Manager, California
It has been a pleasure working with you and your team. The project was carried out to the highest standard and delivered in a timely manner. I will definitely recommend Avance Biosciences’ services to colleagues and friends.
Senior Scientist, Singapore
When you partner with Avance Biosciences, you gain a CRO partner that is creative, collaborative and dedicated to sound science with a focus on the regulatory requirements our partners require. Contact our technical staff to discuss how we can support you in your project!
